論文

査読有り 国際誌
2009年9月

Role of pathogenic T cells and autoantibodies in relapse and progression of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in LEW.1AV1 rats.

Immunology
  • Yoh Matsumoto
  • ,
  • Il-Kwon Park
  • ,
  • Keiko Hiraki
  • ,
  • Shin Ohtani
  • ,
  • Kuniko Kohyama

128
1 Suppl
開始ページ
e250-61
終了ページ
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1111/j.1365-2567.2008.02955.x

Accumulating evidence suggests that T cells and autoantibodies reactive with myelin oligodendrocyte glycoprotein (MOG) play a critical role in the pathogenesis of multiple sclerosis (MS). In the present study, we have tried to elucidate the pathomechanisms of development and progression of the disease by analysing T cells and autoantibodies in MOG-induced rat experimental autoimmune encephalomyelitis (EAE), which exhibits various clinical subtypes mimicking MS. Analysis using overlapping peptides revealed that encephalitogenic epitopes resided in peptide 7 (P7, residue 91-108) and P8 (residue 103-125) of MOG. Immunization with MOGP7 and MOGP8 induced relapsing-remitting or secondary progressive EAE. T cells taken from MOG-immunized and MOGP7-immunized rats responded to MOG and MOGP7 and sera from MOG-immunized rats reacted to MOG and MOGP1. Significant epitope spreading was not observed at either T-cell or antibody levels. Interestingly, sera from MOGP7-immunized rats with clinical signs did not react to MOG and MOG peptides throughout the observation period, suggesting that disease development and relapse in MOGP7-induced EAE occur without autoantibodies. However, MOGP7 immunization with adoptive transfer of anti-MOG antibodies aggravated the clinical course of EAE only slightly. Analysis of antibodies against conformational epitope (cme) suggests that anti-MOG(cme) may play a role in the pathogenicity of anti-MOG antibodies. Collectively, these findings demonstrated that relapse of a certain type of MOG-induced EAE occurs without autoantibodies but that autoantibodies may play a role in disease progression. Relapses and the progression of MS-mimicking EAE are differently immunoregulated so immunotherapy should be designed appropriately on the basis of precise information.

リンク情報
DOI
https://doi.org/10.1111/j.1365-2567.2008.02955.x
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/19175799
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753944
ID情報
  • DOI : 10.1111/j.1365-2567.2008.02955.x
  • PubMed ID : 19175799
  • PubMed Central 記事ID : PMC2753944

エクスポート
BibTeX RIS